Global Hospital Infection Therapeutics Market 2015-2019




$ 2500

In Stock

About hospital-acquired infections
Hospital-acquired diseases are also known as nosocomial infections that are acquired in hospitals and other healthcare facilities. These infections are classified only when a patient is admitted for reasons other than the infections and are caused by bacteria, fungi, parasites, or viruses. Most common types of hospital-acquired infections are SSIs, UTIs, bloodstream infections, pneumococcal infections, MRSA, and gastrointestinal illnesses. These infections appear between 48 hours and four days after a patient is admitted and are usually related to a treatment of procedure used to treat or diagnose the patient's initial illness or injury. Hospital-acquired diseases are preventable through adherence to strict guidelines and less usage of invasive equipment that must be followed by healthcare professionals while caring for the patient. Anti-infective drugs are used for the treatment of these infections. These infections can be minimized by following proper infection control measures in the hospitals and healthcare institutions.

Technavio's analysts forecast the global hospital infection therapeutics market to grow at a CAGR of 3.24% over the period 2014-2019.

Covered in this report
The report covers the present scenario and growth prospects of the global hospital infection therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of drugs used in the treatment of various hospital-acquired infections such as bloodstream infections, Clostridium difficile infections, hospital-acquired pneumonia, surgical site infections, and urinary tract infections.

Technavio's report, Global Hospital Infection Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global hospital infection therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

Key vendors

Other prominent vendors
Abbott Laboratories
AmpliPhi Biosciences
Angelini Pharma
Aridis Pharmaceuticals
Durata Therapeutics
F. Hoffmann-La Roche
Isis Pharmaceuticals
Johnson & Johnson
Ligand Pharmaceuticals
Massachusetts Biological Laboratories
Meiji Seika Pharma
Melinta Therapeutics
Tetraphase Pharmaceuticals
The Medicines Company

Key market driver
Development of multidrug resistant variants
For a full, detailed list, view our report

Key market challenge
Rise in number of infection control programs
For a full, detailed list, view our report

Key market trend
Patient assistance programs
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2019 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?